Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results
Seladelpar demonstrated durable improvements in cholestatic biomarkers and pruritus in patients with primary biliary cholangitis with up to 2 years of treatment and remained overall safe with long-term use. Clinicaltrials.gov: NCT03301506.
Authors
- Marlyn J. Mayo (ORCID: https://orcid.org/0000-0002-4874-7010)
- Sarah Proehl (ORCID: https://orcid.org/0009-0008-8255-3560)
- John M. Vierling (ORCID: https://orcid.org/0000-0001-5547-6020)
- Aliya Gulamhusein (ORCID: https://orcid.org/0000-0003-4648-4736)
- Daria B. Crittenden (ORCID: https://orcid.org/0000-0002-8202-2072)
- Gideon M. Hirschfield (ORCID: https://orcid.org/0000-0002-6736-2255)
- Christopher L. Bowlus (ORCID: https://orcid.org/0000-0002-3906-6811)
- Charles A. McWherter (ORCID: https://orcid.org/0000-0002-7613-3008)
- Stuart C. Gordon (ORCID: https://orcid.org/0000-0001-8666-3849)
- Cynthia Levy (ORCID: https://orcid.org/0000-0001-5498-6037)
- Carrie Heusner
- Palak Trivedi (ORCID: https://orcid.org/0000-0002-4009-8087)
- María‐Carlota Londoño (ORCID: https://orcid.org/0000-0002-6533-1586)
- Ira M. Jacobson (ORCID: https://orcid.org/0000-0003-1803-2214)
- Eric Lawitz (ORCID: https://orcid.org/0000-0002-4234-224X)
- Peter Buggisch (ORCID: https://orcid.org/0000-0002-3076-3960)
- Andreas Emanuel Kremer (ORCID: https://orcid.org/0000-0002-9263-948X)
- Christophe Corpechot (ORCID: https://orcid.org/0000-0002-7920-9784)
- Kris V. Kowdley (ORCID: https://orcid.org/0000-0002-8553-3652)
- David E. Jones (ORCID: https://orcid.org/0000-0002-0083-5564)
- Shuqiong Zhuo
Institutions
- University of Miami (US)
- The University of Texas at San Antonio Health Science Center (US)
- Baylor College of Medicine (US)
- University of Zurich (CH)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Toronto General Hospital (CA)
- Henry Ford Hospital (US)
- National Institute for Health and Care Research (GB)
- Sorbonne Université (FR)
- NYU Langone Health (US)
- NIHR Birmingham Liver Biomedical Research Unit (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- University Hospital of Zurich (CH)
- Hôpital Saint-Antoine (FR)
- Centro de Investigación Biomédica en Red (ES)
- Hospital Clínic de Barcelona (ES)
- Liver Institute Northwest (US)
- Hamburg Institut (Germany) (DE)
- Texas Liver Institute (US)
- Gilead Sciences (United States) (US)
- CymaBay Therapeutics (United States) (US)
- ERN GUARD-Heart (NL)
- Fundació Clínic per a la Recerca Biomèdica (ES)
- Universitat de Barcelona (ES)
- University of Birmingham (GB)
- University of California, Davis (US)
- The University of Texas Southwestern Medical Center (US)
- Michigan State University (US)
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-06-24
- DOI
- https://doi.org/10.14309/ajg.0000000000003603
- Citations
- 4
- Primary Topic
- Pediatric Hepatobiliary Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.03